EFFECTS OF CORYNEBACTERIUM PARVUM ON IMMUNITY.BERD D.1978; PHARMACOL. AND THERAPEUT., A; G.B.; DA. 1978; VOL. 2; NO 2; PP. 373-395; BIBL. 4 P.Article

LABORATORY IDENTIFICATION OF CLINICALLY IMPORTANT AEROBIC ACTINOMYCETESBERD D.1973; APPL. MICROBIOL.; U.S.A.; DA. 1973; VOL. 25; NO 4; PP. 665-681; BIBL. 22REF.Serial Issue

PERITONEAL MACROPHAGE RESPONSE TO LEUKEMIA L1210 IN SYNGENEIC MICE.BERD D; PREHN RT.1977; J. NATION. CANCER INST.; U.S.A.; DA. 1977; VOL. 58; NO 6; PP. 1729-1734; BIBL. 12 REF.Article

EVALUATION OF A "NUDE" MOUSE-HUMAN TUMOR PANEL AS A PREDICTIVE SECONDARY SCREEN FOR CANCER CHEMOTHERAPEUTIC AGENTSBELLET RE; DANNA V; MASTRANGELO MJ et al.1979; J. NATION. CANCER INST.; USA; DA. 1979; VOL. 63; NO 5; PP. 1185-1188; BIBL. 38 REF.Article

PHASE II TRIAL OF VM-26 IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA.BELLET RE; CATALANO RB; MASTRANGELO MJ et al.1978; CANCER TREATM. REP.; U.S.A.; DA. 1978; VOL. 62; NO 3; PP. 445-447; BIBL. 5 REF.Article

Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subsetBERD, D; MASTRANGELO, M. J.Cancer research (Baltimore). 1987, Vol 47, Num 12, pp 3317-3321, issn 0008-5472Article

AUGMENTATION OF THE HUMAN IMMUNE RESPONSE BY CYCLOPHOSPHAMIDEBERD D; MASTRANGELO MJ; ENGSTROM PF et al.1982; CANCER RESEARCH; ISSN 0008-5472; USA; DA. 1982; VOL. 42; NO 11; PP. 4862-4866; BIBL. 19 REF.Article

Cancer vaccines : Reborn or just recycled?BERD, D.Seminars in oncology. 1998, Vol 25, Num 6, pp 605-610, issn 0093-7754Article

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cellsBERD, D; MASTRANGELO, M. J.Cancer research (Baltimore). 1988, Vol 48, Num 6, pp 1671-1675, issn 0008-5472Article

Depletion of suppressor-cytotoxic T-lymphocytes by administration of a murine monoclonal antibodyBERD, D; MASTRANGELO, M. J.Cancer research (Baltimore). 1987, Vol 47, Num 10, pp 2727-2732, issn 0008-5472Article

EFFECT OF 1-(2-CHLOROETHYL)-3-(4-METHYLCYCLOHEXYL)-1-NITROSOUREA ADJUVANT THERAPY ON THE IMMUNE RESPONSE OF PATIENTS WITH MALIGNANT MELANOMABERD D; WILSON EJ; BELLET RE et al.1979; CANCER RES.; USA; DA. 1979; VOL. 39; NO 11; PP. 4472-4476; BIBL. 21 REF.Article

PHASE II STUDY OF SUBCUTANEOUSLY ADMINISTERED 5-AZACYTIDINE (NSC-102816) IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA.BELLET RE; CATALANO RB; MASTRANGELO MJ et al.1978; MED. PEDIATR. ONCOL.; U.S.A.; DA. 1978; VOL. 4; NO 1; PP. 11-15; BIBL. 12 REF.Article

LONG-TERM REMISSION IN DIFFUSE HISTIOCYTIC LYMPHOMA TREATED WITH COMBINATION SEQUENTIAL CHEMOTHERAPY = REMISSION A LONG TERME DANS LE LYMPHOME HISTIOCYTAIRE DIFFUS TRAITE PAR LA CHIMIOTHERAPIE SEQUENTIELLE D'ASSOCIATIONBERD D; CORNOG J; DECONTI RC et al.1975; CANCER; U.S.A.; DA. 1975; VOL. 35; NO 4; PP. 1050-1054; BIBL. 8REF.Article

METASTATIC UVEAL MELANOMA. HEPATIC CELL-SURFACE ENZYMES, ISOENZYMES, AND SERUM SIALIC ACID LEVELS IN EARLY METASTATIC DISEASEDONOSO LA; NAGY RM; BROCKMAN RJ et al.1983; ARCHIVES OF OPHTHALMOLOGY; ISSN 0003-9950; USA; DA. 1983; VOL. 101; NO 5; PP. 791-794; BIBL. 17 REF.Article

Depletion of T-cells with the CD4+CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanomaCARDI, G; MASTRAGENLO, M. J; BERD, D et al.Cancer research (Baltimore). 1989, Vol 49, Num 23, pp 6562-6565, issn 0008-5472, 4 p.Article

CURRENT CONCEPTS OF THE BIOLOGY OF HUMAN CUTANEOUS MALIGNANT MELANOMA.CLARK WH JR; MASTRANGELO MJ; AINSWORTH AM et al.1977; ADV. CANCER RES.; U.S.A.; DA. 1977; VOL. 24; PP. 267-338; BIBL. 7 P.Article

Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccineBERD, D; MAGUIRE, H. C; MASTRANGELO, M. J et al.Cancer immunology and immunotherapy. 1994, Vol 39, Num 3, pp 141-147, issn 0340-7004Article

Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigensBERD, D; HERLYN, M; KOPROWSKI, H et al.Cancer research (Baltimore). 1989, Vol 49, Num 23, pp 6840-6844, issn 0008-5472, 5 p.Article

Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamideBERD, D; MAGUIRE, H. C. JR; MASTRANGELO, M. J et al.Cancer research (Baltimore). 1984, Vol 44, Num 11, pp 5439-5443, issn 0008-5472Article

Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccineSATO, T; MAGUIRE, H. C; MASTRANGELO, M. J et al.Clinical immunology and immunopathology (Print). 1995, Vol 74, Num 1, pp 35-43, issn 0090-1229Article

Autologous melanoma vaccine induces inflammatory responses in melanoma metastases : relevance to immunologic regression and immunotherapyMURPHY, G. F; RADU, A; KAMINER, M et al.Journal of investigative dermatology. 1993, Vol 100, Num 3, pp 335S-341S, issn 0022-202XArticle

Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamideBERD, D; MAGUIRE, H. C. JR; MASTRANGELO, M. J et al.Cancer research (Baltimore). 1986, Vol 46, Num 5, pp 2572-2577, issn 0008-5472Article

Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer = Modification de l'activité suppressive induite par la concanavaline A après administration de cyclophosphamide chez des malades ayant un cancer avancéBERD, D; MAGUIRE, H. C. JR; MASTRANGELO, M. J et al.Cancer research (Baltimore). 1984, Vol 44, Num 3, pp 1275-1280, issn 0008-5472Article

Time to recurrence varies inversely with thickness in clinical stage 1 cutaneous melanomaSCHULTZ, S; KANE, M; ROUSH, R et al.Surgery, gynecology & obstetrics. 1990, Vol 171, Num 5, pp 393-397, issn 0039-6087, 5 p.Article

Melanoma and vitiligo : immunology's Grecian urnBERD, D; MASTRANGELO, M. J; LATTIME, E et al.Cancer immunology and immunotherapy. 1996, Vol 42, Num 5, pp 263-267, issn 0340-7004Article